Differentiating Alzheimer disease-associated aggregates with small molecules

Neurobiology of Disease

Volumn 28, Issue 3, 2007, Pages 251-260

  Honson, Nicolette S ^a   Johnson, Ronald L ^b   Huang, Wenwei ^b   Inglese, James ^b   Austin, Christopher P ^b   Kuret, Jeff ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Alzheimer disease; Contrast agents; Diagnosis; Neurofibrillary tangle; Tau

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; ANILINE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; DIRECT YELLOW 7; DOXORUBICIN; PROTEIN INHIBITOR; QUINOXALINE DERIVATIVE; TAU PROTEIN; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; CHEMICAL BOND; DISEASE ASSOCIATION; DRUG PROTEIN BINDING; DRUG SCREENING; FEASIBILITY STUDY; FLUORESCENCE ANALYSIS; MOLECULAR PROBE; PRIORITY JOURNAL; PROTEIN AGGREGATION;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT DYES; HUMANS; MASS SPECTROMETRY; NEUROFIBRILLARY TANGLES; PEPTIDE LIBRARY; SENILE PLAQUES; TAU PROTEINS; THIAZINES; THIAZOLES;

EID: 36148962734     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2007.07.018     Document Type: Article

References (50)

1. Agdeppa E.D., et al. 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. Mol. Imaging Biol. 5 (2003) 404-417
2. Antonov L., et al. Theoretical investigations on the tautomerism of 1-phenylazo-4-naphthol and its isomers. Dyes Pigm. 38 (1998) 157-164
3. Berriman J., et al. Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9034-9038
4. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82 (1991) 239-259
5. Buee L., et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33 (2000) 95-130
6. Caprathe, B.W. et al., 1999. Method of imaging amyloid deposits. U.S. Patent 6,001,331.
7. Carmel G., et al. The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J. Biol. Chem. 271 (1996) 32789-32795
8. 50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
9. Chirita C.N., and Kuret J. Evidence for an intermediate in tau filament formation. Biochemistry 43 (2004) 1704-1714
10. Chirita C.N., et al. Anionic micelles and vesicles induce tau fibrillization in vitro. J. Biol. Chem. 278 (2003) 25644-25650
11. Chirita C.N., et al. Triggers of full-length tau aggregation: a role for partially folded intermediates. Biochemistry 44 (2005) 5862-5872
12. Cohen T., et al. Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry 45 (2006) 4727-4735
13. Conway K.A., et al. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 (2001) 1346-1349
14. Copeland R.A. Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists (2005), Wiley, Hoboken, N.J
15. Crowe A., et al. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem. Biophys. Res. Commun. 358 (2007) 1-6
16. Duyckaerts C., and Hauw J.J. Prevalence, incidence and duration of Braak's stages in the general population: can we know?. Neurobiol. Aging 18 (1997) 362-369
17. Friedhoff P., et al. Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry 37 (1998) 10223-10230
18. Gazit E. A possible role for pi-stacking in the self-assembly of amyloid fibrils. FASEB J. 16 (2002) 77-83
19. Ghoshal N., et al. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp. Neurol. 177 (2002) 475-493
20. Guillozet-Bongaarts A.L., et al. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol. Aging 26 (2005) 1015-1022
21. Hebert L.E., et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60 (2003) 1119-1122
22. Hyman B.T. The neuropathological diagnosis of Alzheimer's disease: clinical-pathological studies. Neurobiol. Aging 18 (1997) S27-S32
23. Inglese J., et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 11473-11478
24. Jellinger K.A. Lewy body-related alpha-synucleinopathy in the aged human brain. J. Neural Transm. 111 (2004) 1219-1235
25. Khatoon S., et al. Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J. Neurochem. 59 (1992) 750-753
26. King M.E., et al. Ligand-dependent tau filament formation: implications for Alzheimer's disease progression. Biochemistry 38 (1999) 14851-14859
27. Klunk W.E., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55 (2004) 306-319
28. Klunk W.E., et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 25 (2005) 10598-10606
29. Kotzbauer P.T., et al. Lewy body pathology in Alzheimer's disease. J. Mol. Neurosci. 17 (2001) 225-232
30. Krebs M.R., et al. The binding of thioflavin-T to amyloid fibrils: localisation and implications. J. Struct. Biol. 149 (2005) 30-37
31. Kung M.P., et al. Detection of amyloid plaques by radioligands for Aβ40 and Aβ42: potential imaging agents in Alzheimer's patients. J. Mol. Neurosci. 20 (2003) 15-24
32. Lockhart A., et al. Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J. Biol. Chem. 280 (2005) 7677-7684
33. Masliah E., et al. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology 43 (1993) 192-197
34. Mena R., et al. Monitoring pathological assembly of tau and beta-amyloid proteins in Alzheimer's disease. Acta Neuropathol. (Berl.) 89 (1995) 50-56
35. Morsch R., et al. Neurons may live for decades with neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 58 (1999) 188-197
36. Necula M., and Kuret J. Electron microscopy as a quantitative method for investigating tau fibrillization. Anal. Biochem. 329 (2004) 238-246
37. Necula M., et al. Rapid anionic micelle-mediated α-synuclein fibrillization in vitro. J. Biol. Chem. 278 (2003) 46674-46680
38. Okamura N., et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J. Neurosci. 25 (2005) 10857-10862
39. Petkova A.T., et al. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 307 (2005) 262-265
40. Petkova A.T., et al. Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. Biochemistry 45 (2006) 498-512
41. Pickhardt M., et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer paired helical filaments in vitro and in cells. J. Biol. Chem. 280 (2005) 3628-3635
42. Royall D.R., et al. Pathological determinants of the transition to clinical dementia in Alzheimer's disease. Exp. Aging Res. 28 (2002) 143-162
43. Schweers O., et al. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J. Biol. Chem. 269 (1994) 24290-24297
44. Stine Jr. W.B., et al. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem. 278 (2003) 11612-11622
45. Terry R.D., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30 (1991) 572-580
46. Wang J., et al. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158 (1999) 328-337
47. Wilson D.M., and Binder L.I. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am. J. Pathol. 150 (1997) 2181-2195
48. Wischik, C.M., et al., 2004. Neurofibrillary labels. U.S. Patent Application 0213736 A1.
49. Ye L., et al. Characterisation of the binding of amyloid imaging tracers to rodent Abeta fibrils and rodent-human Abeta co-polymers. Biochem. Biophys. Res. Commun. 347 (2006) 669-677
50. Zhu M., et al. The flavonoid baicalein inhibits fibrillation of a-synuclein and disaggregates existing fibrils. J. Biol. Chem. 279 (2004) 26846-26857